Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

Xueping Qu(Unknown), Carlos Bais(Eos Neuroscience (United States))
Nature Communications
May 9, 2025
Cited by 16


Related Papers